1,259,876 Shares in Fennec Pharmaceuticals Inc (NASDAQ:FENC) Bought by Rosalind Advisors Inc.

Rosalind Advisors Inc. purchased a new position in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,259,876 shares of the company's stock, valued at approximately $7,962,000. Fennec Pharmaceuticals makes up 4.0% of Rosalind Advisors Inc.'s holdings, making the stock its 10th largest holding. Rosalind Advisors Inc. owned 4.57% of Fennec Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in FENC. State Street Corp increased its position in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company's stock worth $1,641,000 after purchasing an additional 7,053 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Fennec Pharmaceuticals by 10.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company's stock worth $386,000 after purchasing an additional 5,694 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in shares of Fennec Pharmaceuticals during the 3rd quarter worth about $264,000. Clayton Partners LLC purchased a new stake in shares of Fennec Pharmaceuticals during the fourth quarter worth about $256,000. Finally, Rhumbline Advisers raised its position in shares of Fennec Pharmaceuticals by 12.9% in the fourth quarter. Rhumbline Advisers now owns 34,299 shares of the company's stock valued at $217,000 after buying an additional 3,911 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other news, Director Rosty Raykov sold 10,000 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total transaction of $67,900.00. Following the completion of the sale, the director now directly owns 68,725 shares of the company's stock, valued at $466,642.75. The trade was a 12.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 31,186 shares of company stock valued at $203,389 over the last quarter. Company insiders own 10.98% of the company's stock.

Fennec Pharmaceuticals Stock Up 0.6 %

Shares of FENC stock traded up $0.04 during trading hours on Wednesday, hitting $6.47. 46,767 shares of the company were exchanged, compared to its average volume of 109,790. Fennec Pharmaceuticals Inc has a 1 year low of $3.96 and a 1 year high of $11.37. The firm has a fifty day moving average of $6.48 and a 200 day moving average of $5.69. The firm has a market cap of $178.49 million, a PE ratio of -64.69 and a beta of 0.36.

Analysts Set New Price Targets

A number of brokerages recently issued reports on FENC. HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday, March 11th. Wedbush restated an "outperform" rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a report on Monday, March 10th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.